Introduction {#Sec1}
============

The progressive nature of type 2 diabetes mellitus (T2DM) necessitates that medications are continually optimized to achieve and maintain recommended or individualized metabolic goals \[[@CR1], [@CR2]\]. In time, insulin therapy is almost inevitably required as islet B cell function declines, and with time, insulin regimens have to be further optimized to maintain control to target. However, in some people, overly rigorous intensification of blood glucose control can impair a person's health by leading to increased risk of hypoglycemia \[[@CR3]\]. This gives rise to challenges in identifying and implementing suitable insulin regimens for individuals in clinical practice.

Information to assist such decision making can come not only from randomized clinical trials (RCTs), but also from non-interventional studies that allow for selection of a larger, more representative heterogeneous patient population, also allowing collection of larger datasets of efficacy, safety, and tolerability outcomes.

Insulin aspart (aspart) is a rapid-acting meal-time insulin analogue studied in a number of RCTs \[[@CR4], [@CR5]\]. In several RCTs, meal-time insulin alone was started in people with T2DM, on occasion with optimization of therapy by later addition of a basal insulin \[[@CR6]--[@CR8]\]. It has been suggested that this is appropriate as the progression of insulin deficiency in T2DM follows from an initial insufficiency of postprandial glucose control \[[@CR9]\].

Postprandial hyperglycemia has been putatively linked to increased risks of macrovascular disease, diabetic retinopathy, and decreased myocardial blood volume and myocardial blood flow \[[@CR10]--[@CR13]\], and studies show aspart lowers postprandial plasma glucose (PPPG) levels to a greater extent than unmodified human insulin \[[@CR14]\]. Insulin aspart is also available as a premix preparation (biphasic insulin aspart) and can be combined with a basal insulin in a meal-time + basal insulin regimen. In the 4T (Treating to Target in Type 2 diabetes) study, blood glucose control and hypoglycemia at 3 years were comparable for basal insulin added to aspart, aspart added to biphasic insulin aspart, and aspart added to a basal insulin \[[@CR7]\].

The A~1~chieve study \[[@CR15]\] included people with T2DM on aspart, biphasic insulin aspart 30 (aspart premix), and insulin detemir in 28 countries in routine clinical practice, albeit for a shorter period of time. The present subgroup analysis was conducted to investigate the clinical safety, tolerability, and effectiveness of aspart therapy in a cohort of insulin-naïve and insulin-experienced patients starting aspart alone at baseline and continuing with aspart alone, switching to aspart premix, or adding a basal insulin during the study.

Materials and Methods {#Sec2}
=====================

Study Design {#Sec3}
------------

A~1~chieve was a multinational, 24-week, non-interventional study to assess the safety and effectiveness of the insulin analogs, aspart (NovoRapid^®^, Novo Nordisk, Bagsvaerd, Denmark), aspart premix (NovoMix^®^, Novo Nordisk), and detemir (Levemir^®^, Novo Nordisk), in routine clinical care \[[@CR15]\]. The participating countries were grouped into seven regions: China, South Asia (Bangladesh, India, Pakistan), East Asia (Indonesia, Korea, Malaysia, Philippines, Singapore, Taiwan), North Africa (Algeria, Morocco, Tunisia, Libya), Middle East + Gulf (Egypt, Iran, Jordan, Turkey, Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, United Arab Emirates, Yemen), Latin America (Argentina, Mexico), and Russia. This sub-analysis was conducted in a cohort of previously insulin-naïve or insulin-experienced patients starting aspart therapy at baseline and then continuing on aspart alone, switching to aspart premix, or adding a basal insulin, at the discretion of their physicians, during the 24-week study period.

There were no pre-defined study procedures and the participating physicians were responsible for all aspects of the patient care, including the decision to appropriately modify therapies. Study insulins were commercially available and used as per routine clinical practice. Data for analysis were collected for pre-study, baseline (insulin day 1), interim visit (around 12 weeks from baseline), and final visit (around 24 weeks from baseline). The use of oral glucose-lowering drugs (OGLDs) was permitted throughout the study at the physicians' discretion.

Patients {#Sec4}
--------

Any participant who started therapy on aspart alone in the 4 weeks prior to baseline and continued using aspart alone, switched to aspart premix, or added a basal insulin by study end was eligible for this sub-analysis. Women who were pregnant, breast-feeding, or had the intention of becoming pregnant were not included.

Compliance with ethics {#Sec5}
----------------------

This article does not contain any new studies with human or animal subjects performed by any of the authors. All participants provided signed informed consent and ethics committee approvals were obtained for each participating country.

Assessments and Outcomes {#Sec6}
------------------------

The primary outcome measure was the incidence of serious adverse drug reactions (SADRs), including major hypoglycemic events. Secondary outcomes included the number of serious adverse events (SAEs), and the change in the proportion of participants that reported hypoglycemic events during the 4 weeks preceding baseline and week 24. A hypoglycemic event was defined as an event with symptoms of hypoglycemia that resolved with oral carbohydrate intake, glucagon or intravenous glucose, or any symptomatic or asymptomatic event with a plasma glucose level of 3.1 mmol/l (56 mg/dl). Nocturnal hypoglycemic events were defined as individualized symptomatic events consistent with hypoglycemia, occurring during sleep, after the evening insulin injection and before getting up in the morning, and if relevant, before morning determination of fasting plasma glucose (FPG) and the morning insulin injection. Major hypoglycemic events were defined as events with severe central nervous system symptoms consistent with hypoglycemia in which the patient was unable to self-treat and characterized by either a plasma glucose level of 3.1 mmol/l (56 mg/dl), or reversal of symptoms after either food intake, glucagon or intravenous glucose administration.

Other secondary outcomes included the change from baseline to week 24 in HbA~1c~, FPG, PPPG, systolic blood pressure, body weight, and lipid profile. Health-related quality of life (HRQoL) was assessed based on the change in visual analog scores (VAS) of the EQ-5D questionnaire \[[@CR16]\] from baseline to week 24.

Laboratory measurements were performed by local laboratories following local standardization and quality control procedures.

Statistical Analysis {#Sec7}
--------------------

Statistical analyses were performed for the groups that continued aspart alone, switched to aspart premix or added a basal insulin during the study. Continuous and discrete variables were summarized using descriptive statistics (mean, SD) and frequency tables (*n*,%), respectively. Two-sided tests at a pre-specified 5% significance level were used for all statistical analyses. The change from baseline to study end in the proportion of patients reporting at least one hypoglycemic event was analyzed using McNemar's test. The change from baseline to study end for all other outcomes was analyzed using Student's paired *t* test. All data were analyzed by Novo Nordisk personnel using SAS^®^ (Version 9.1.3, SAS, Cary, NC, USA).

Results {#Sec8}
=======

Baseline Characteristics and Glucose-Lowering Regimens {#Sec9}
------------------------------------------------------

A total of 3,898 people with T2DM started therapy with aspart alone ± OGLDs at baseline, of whom 3,313 patients had data available by study end. The remaining 585 patients were withdrawn due to loss of contact (434 patients), adverse drug reaction (1 patient), and other reasons (150 patients). By region, 1,244 participants from China, 1,851 from South Asia, 494 from East Asia, 70 from North Africa, 197 from Middle East + Gulf, 19 from Latin America and 23 from Russia started aspart alone ± OGLDs at baseline.

The physicians' main reason for starting aspart therapy was to improve glycemic control (92.2% for participants continuing aspart alone, 96.7% for switchers to aspart premix and 93.0% for those adding a basal insulin).

Of the 3,313 completers, 1,545 patients (46.6%) continued with aspart alone, 1,379 (41.6%) switched to aspart premix, and 214 (6.5%) added basal insulin by week 24. Other participants switched to detemir (39, 1.2%), added aspart premix to aspart (86, 2.6%) or moved to diverse other regimens (50, 1.5%), and are not discussed further as the number of patients was too low for statistical significance. Baseline characteristics for the three groups analyzed are presented in Table [1](#Tab1){ref-type="table"}.Table 1Demographic and baseline characteristicsInsulin regimen at week 24Aspart aloneAspart premixAspart + basal *n*1,5451,379214 Male/female (%)58.8/41.258.0/42.051.4/48.6 Age (years)53.0 (13.3)54.6 (12.0)53.4 (13.0) Body weight (kg)67.7 (13.0)70.0 (11.9)70.0 (15.7) Body mass index (kg/m^2^)25.2 (4.0)25.7 (3.9)25.8 (4.9) Duration of diabetes (years)7.4 (6.3)6.5 (5.3)8.5 (6.7) Duration on insulin (years)1.1 (2.7)0.8 (2.1)1.8 (3.3) HbA~1c~ (%/mmol/mol)9.4 (1.9)/79 (21)9.6 (1.7)/81 (19)9.4 (2.0)/79 (22)Oral glucose-lowering drugs, *n* (%) Total *n*98386091 Metformin772 (78.5)640 (74.4)68 (74.7) Sulfonylureas370 (37.6)270 (31.4)20 (22.0) One604 (61.4)604 (70.2)63 (69.2) Two340 (34.6)237 (27.6)22 (24.2) \>Two39 (4.0)19 (2.2)6 (6.6)Data are mean (SD), or as stated

The majority of participants were on at least one OGLD at baseline with metformin and sulfonylureas being the most commonly used OGLDs in all groups (Table [1](#Tab1){ref-type="table"}). At week 24, the proportions of patients on 1 OGLD, 2 OGLDs, and more than 2 OGLDs were 55.5, 41.3, and 3.2%, respectively, in the aspart group; 70.6, 27.0, and 2.5%, respectively, in the aspart premix group, and 75.8, 17.6, and 6.6%, respectively, in the aspart + basal insulin group.

Insulin Dose and Frequency of Administration {#Sec10}
--------------------------------------------

Insulin doses and administration frequencies for each group pre-study, at baseline and at week 24 are presented in Table [2](#Tab2){ref-type="table"}. The mean daily ± SD insulin dose by weight at week 24 was 0.43 ± 0.21 U/kg/day in the aspart alone group, 0.42 ± 0.19 U/kg/day in the aspart premix group, and 0.72 ± 0.29 U/kg/day in the aspart + basal group.Table 2Insulin dose and dosing frequency at pre-study, baseline and week 24Insulin regimen at week 24Aspart aloneAspart premixAspart + basalInsulin dose (U/day) *n*1,5451,379214 Pre-study33.0 (18.5)34.8 (16.4)39.6 (23.6) Baseline27.5 (13.5)30.3 (12.0)26.3 (14.1) Week 2428.0 (13.3)28.6 (13.1)49.1 (22.3)Insulin dose by body weight (U/kg/day) *n*1,4681,347199 Pre-study0.49 (0.28)0.50 (0.24)0.57 (0.32) Baseline0.42 (0.22)0.44 (0.18)0.40 (0.22) Week 240.43 (0.21)0.42 (0.19)0.72 (0.29)Daily dose frequency Pre-study, *n* (%)423332125 Once89 (21.0)63 (19.0)39 (31.2) Twice201 (47.5)205 (61.7)44 (35.2) Thrice102 (24.1)40 (12.0)22 (17.6) \>Thrice31 (7.3)24 (7.2)20 (16.0) Baseline, *n* (%)1,5451,378213 Once98 (6.3)59 (4.3)24 (11.3) Twice592 (38.3)380 (27.6)19 (8.9) Thrice802 (51.9)807 (58.6)154 (72.3) \>Thrice53 (3.4)132 (9.6)16 (7.5) Week 24, *n* (%)1,5441,379214 Once94 (6.1)63 (4.6)0 Twice641 (41.5)1,181 (85.6)17 (7.9) Thrice767 (49.7)132 (9.6)24 (11.2) \>Thrice42 (2.7)3 (0.2)173 (80.8)Data are mean (SD), or as stated

In the aspart alone group at baseline, 51.9% of participants used it thrice daily, evolving in those continuing aspart alone to 41.5% twice daily and 49.7% thrice daily by week 24. In the group switching to aspart premix, 58.6% started aspart thrice daily at baseline, while 85.6% were on twice daily aspart premix at week 24. In the group adding a basal insulin, 72.3% and 80.8% were administering aspart at least thrice daily at baseline and week 24, respectively.

SADRs and SAEs {#Sec11}
--------------

No SADRs were reported in any of the participants during the study. Four SAEs (upper gastrointestinal hemorrhage, hepatic coma, chronic renal failure, and vascular stenosis) were reported in those continuing aspart alone, two (pyrexia and herpes zoster) in those changing to premix, and one (melaena) in those adding a basal insulin. All SAEs were considered unlikely to be related to the study drugs.

Hypoglycemia {#Sec12}
------------

Data for hypoglycemia in the 4 weeks pre-baseline and pre-week 24 are presented in Table [3](#Tab3){ref-type="table"}. A statistically significant decrease in the proportion of patients reporting confirmed any-time hypoglycemia between baseline and week 24 was noted in the aspart alone group (11.2% versus 4.1%, *p* \< 0.001), and the aspart + basal insulin group (13.1% versus 7.5%, *p* = 0.040), while there was no statistically significant change in the aspart premix group (5.1% versus 3.7%, NS). No events of major hypoglycemia were reported in the 4 weeks preceding week 24 in any of the groups.Table 3Hypoglycemia in the 4 weeks before baseline and before week 24Insulin regimen at week 24Aspart aloneAspart premixAspart + basalRate (event/person-year)Percent with at least 1 event (%)Rate (event/person-year)Percent with at least 1 event (%)Rate (event/person-year)Percent with at least 1 event (%)Overall Baseline3.8211.21.565.14.6213.1 Week 241.064.11.093.71.767.5 *p*\<0.0010.0660.040Major Baseline0.431.90.161.10.361.4 Week 240.00.00.00.00.00.0 *p*\<0.0010.0010.083Minor Baseline3.3910.61.404.64.2512.6 Week 241.064.11.093.71.767.5 *p*\<0.0010.2350.063Nocturnal Baseline1.125.40.422.01.156.1 Week 240.100.60.261.40.120.9 *p*\<0.0010.1600.005Overall is confirmed or major anytime hypoglycemia*p*-value was calculated using McNemar's test for the proportion of patients experiencing hypoglycemia

From baseline to week 24, the proportion of patients reporting nocturnal hypoglycemia significantly decreased in the aspart alone group (5.4% versus 0.6%, *p* \< 0.001), and in the aspart + basal insulin group (6.1% versus 0.9%, *p* = 0.005), but not in the aspart premix group (2.0% versus 1.4%, NS).

Blood Glucose Control {#Sec13}
---------------------

The mean HbA~1c~ level decreased similarly from baseline to week 24 in all three groups: from 9.4 ± 1.9% (79 ± 21 mmol/mol) to 7.3 ± 1.1% (56 ± 12 mmol/mol) in the aspart alone group; from 9.6 ± 1.7% (81 ± 19 mmol/mol) to 7.3 ± 0.9% (56 ± 10 mmol/mol) in the aspart premix group; and from 9.4 ± 2.0% (79 ± 22 mmol/mol) to 7.4 ± 1.3% (57 ± 14 mmol/mol) in the aspart + basal insulin group (all *p* \< 0.001, Table [4](#Tab4){ref-type="table"}). At week 24, 36.5, 32.1, and 45.0% of participants in groups ending on aspart alone, aspart premix, and aspart + basal insulin had HbA~1c~ levels \<7.0% (\<53 mmol/mol) compared to 8.6, 4.8, and 6.7% at baseline. The mean FPG and post-breakfast PPPG levels also decreased to a clinically and statistically significant extent in all three groups (all *p* \< 0.001, Table [4](#Tab4){ref-type="table"}).Table 4Blood glucose control at baseline and after 24 weeksInsulin regimen at week 24Aspart aloneAspart premixAspart + basalHbA~1c~ (%/mmol/mol) *n*1,0671,119144 Baseline9.4 (1.9)/79 (21)9.6 (1.7)/81 (19)9.4 (2.0)/79 (22) Week 247.3 (1.1)/56 (12)7.3 (0.9)/56 (10)7.4 (1.3)/57 (14) Change−2.1 (2.0)/−23 (22)−2.3 (1.7)/−25 (19)−2.0 (2.1)/−22 (23) *p*\<0.001\<0.001\<0.001FPG (mmol/L) *n*1,3081,197156 Baseline10.6 (3.5)11.6 (4.2)10.5 (4.4) Week 247.3 (2.0)7.7 (2.4)7.3 (2.8) Change−3.3 (3.2)−3.9 (3.4)−3.2 (4.7) *p*\<0.001\<0.001\<0.001PPPG (mmol/L) *n*991935116 Baseline15.2 (4.7)16.5 (5.3)14.5 (4.8) Week 2410.0 (3.1)11.0 (3.7)9.6 (3.3) Change−5.2 (4.5)−5.5 (4.2)−4.9 (4.9) *p*\<0.001\<0.001\<0.001Data are mean (SD), or as stated*FPG* fasting plasma glucose, *HbA* ~*1c*~ glycated hemoglobin A~1c~, *PPPG* postprandial plasma glucose

Lipids, Body Weight, and Systolic Blood Pressure {#Sec14}
------------------------------------------------

All measures of the lipid profile (Table [5](#Tab5){ref-type="table"}) improved to a similar extent in the three groups, but low ascertainment and thus small numbers meant that this was not confirmed statistically in the aspart + basal insulin group except for total serum cholesterol.Table 5Baseline and 24-week data for blood lipids, body weight and systolic blood pressureInsulin regimen at week 24Aspart aloneAspart premixAspart + basalTotal cholesterol (mmol/l) *n*29732462 Baseline5.1 (1.2)5.2 (1.4)5.0 (1.7) Week 244.6 (0.9)4.7 (1.2)4.6 (1.0) Change−0.4 (1.1)−0.6 (1.3)−0.4 (1.4) *p*\<0.001\<0.0010.03Triglycerides (mmol/l) *n*32232754 Baseline1.9 (1.1)2.0 (1.1)2.0 (1.3) Week 241.7 (0.7)1.8 (0.8)1.9 (0.9) Change−0.3 (0.9)−0.2 (0.9)−0.2 (1.0) *p*\<0.001\<0.0010.21HDL cholesterol (mmol/l) *n*28729850 Baseline1.2 (0.4)1.1 (0.3)1.1 (0.3) Week 241.2 (0.4)1.2 (0.4)1.2 (0.3) Change0.1 (0.4)0.1 (0.3)0.1 (0.2) *p*\<0.0010.0050.057LDL cholesterol (mmol/l) *n*29230651 Baseline3.0 (1.0)3.2 (1.0)2.9 (0.9) Week 242.7 (0.8)2.9 (1.1)2.6 (0.9) Change−0.2 (0.9)−0.4 (1.2)−0.2 (1.0) *p*\<0.001\<0.0010.083Body weight (kg) *n*1,3671,217182 Baseline67.4 (12.8)70.0 (11.7)70.1 (16.2) Week 2467.6 (12.1)70.1 (11.2)71.0 (15.3) Change0.1 (2.7)0.1 (2.6)0.9 (3.5) *p*0.1020.312\<0.001Systolic blood pressure (mmHg) *n*1,0641,055166 Baseline132.3 (17.1)138.7 (22.2)133.0 (18.2) Week 24127.9 (14.4)127.1 (12.0)126.7 (14.2) Change−4.3 (15.3)−11.6 (21.5)−6.3 (14.9) *p*\<0.001\<0.001\<0.001Data are mean (SD), or as stated*HDL* high-density lipoprotein, *LDL* low-density lipoprotein

There was no clinically or statistically significant change in body weight in the aspart alone and aspart premix groups, but a gain of 0.9 ± 3.5 kg by week 24 in the group adding basal insulin was statistically significant (*p* \< 0.001) (Table [5](#Tab5){ref-type="table"}).

Clinically and statistically significant decreases in systolic blood pressure levels were noted in all three groups by 24 weeks (Table [5](#Tab5){ref-type="table"}).

Quality of Life {#Sec15}
---------------

The mean HRQoL improved from baseline to week 24 in all three groups as measured by the EQ-5D VAS score (aspart alone, 64.8 ± 16.7 to 79.2 ± 10.8 points; aspart premix, 61.5 ± 17.6 to 77.1 ± 10.8 points; and aspart + basal insulin, 68.4 ± 18.0 to 77.7 ± 12.2 points; all *p* \< 0.001).

Discussion {#Sec16}
==========

This sub-analysis confirms the clinical safety and effectiveness of aspart therapy, whether administered as prandial insulin alone, as the premixed analogue biphasic insulin aspart (and thus including protaminated aspart) or when combined with a basal insulin in a meal-time + basal regimen. While it is uncommon in global clinical practice to begin any insulin regimen with meal-time insulin alone, of the 66,726 people enrolled in A~1~chieve on four continents, this was the case in 3,898 (5.8%), with some variation from country to country.

Having begun meal-time aspart, adding a basal insulin or switching to a biphasic insulin regimen was common (48%) within 24 weeks and are accepted methods of therapy intensification that allow coverage of both meal-time and basal insulin requirements \[[@CR17], [@CR18]\]. However, by study end a substantial proportion (47%) were still taking aspart alone, suggesting that these patients were then in satisfactory glucose control or were reluctant to further intensify their regimen. Clearly, the majority of study participants were initially seen as having a predominantly meal-time insulin requirement, given the small proportion of participants who subsequently added a basal insulin (7%) to the initial aspart regimen.

Baseline characteristics (age, body weight, and BMI) were broadly similar across the three groups, but A~1~chieve was not a randomized study, and it cannot be assumed that the populations were comparable in other ways. Use of a multiple injection regimen (aspart + basal) offers more opportunity for dose titration, and the higher insulin dose in this group reflects the high dose in the group on aspart + basal insulin in the overall A~1~chieve cohort \[[@CR15]\]. Such people are often judged as more insulin deficient, consistent with this group having modestly longer duration of diabetes from diagnosis (8.5 years) compared with those who continued aspart alone (7.4 years) or changed to aspart premix (6.5 years). The statistically significant improvements in HbA~1c~ were consistent with those reported for the main study and were comparable between the three groups at 24 weeks. The FPG and PPPG levels also improved to clinically large extents in all three groups (all *p* \< 0.001). This is consistent with the observational INSTIGATE study, where useful reductions in FPG levels were also reported from meal-time aspart therapy alone \[[@CR19]\]. Indeed, the improvements in FPG levels with aspart in routine clinical practice are better than found in RCTs \[[@CR20]\] and, together with the improvements in systolic blood pressure, lipid profile and the lack of weight gain, led us to suggest that starting the insulin analogues in A~1~chieve may have also been an opportunity to improve lifestyle measures \[[@CR15]\]. Such changes in lifestyle would be expected to minimize differences between the insulin regimens.

Insulin aspart therapy was well tolerated with no SADRs reported in any group during the study, consistent with the large body of clinical experience gained in the past 10 years. Interestingly, there was a decrease from baseline to week 24 in the proportion of participants reporting both confirmed anytime and nocturnal hypoglycemia in the aspart alone group and the aspart + basal group. The findings are consistent with those from the main study, from a sub-analysis of use of the aspart + basal insulin regimen in older people \[[@CR15], [@CR21]\]. For the aspart premix group, data interpretation is complicated by a lower baseline rate of anytime hypoglycemia, although the 24-week rate is not notably different from the other two groups; however, the change was not statistically significant. While reporting fatigue may have been an issue, or the state of the population in the 4 weeks to baseline, it is again possible that the opportunity of starting insulin aspart was used to enhance lifestyle management, including avoidance of hypoglycemia.

It is encouraging that HRQoL was found to rise in all three groups from baseline to 24 weeks. All three groups used multiple injections, so it seems clear that this did not subtract significantly from the gains that would be associated with the marked improvement of blood glucose control. Gains in HRQoL have been noted in RCTs even where multiple injections were used \[[@CR22]\]. Again, however, it is also possible that the circumstance in which the participants in A~1~chieve started insulin may have resulted in other enhancements of clinical care and that these and the lifestyle changes combined to enhance life quality. The statistically significant improvements seen in the lipid profile in the aspart alone and aspart premix groups, and in total cholesterol in the aspart + basal insulin group may also have contributed to the improved HRQoL at week 24.

Limitations of the A~1~chieve study included the lack of randomization, which may mean that different results in different populations merely reflect different clinical habits or population phenotypes. However, the results here are strikingly similar among the three defined study groups, and the changes within each group sufficiently notable to be of interest without comparison between groups. As this was a non-interventional study, non-standardization of study procedures across sites and regions may also be a factor. Other useful information would have been dietary and exercise changes, circumstances of starting the insulin analog (e.g., in-patient care, referral to a specialist), and non-diabetes-related medications. These, as discussed above, limit data interpretation. Collection of hypoglycemia data based on the patient's recall of hypoglycemic events may have been problematic, particularly in regard of baseline, though if anything the results are seemingly high for that observational point. However, this large, non-interventional study did provide an opportunity to investigate treatment outcomes related to the use of different regimens of aspart therapy in around 3,000 people in routine care in countries with either a lower resource base or recent economic evolution.

Conclusion {#Sec17}
==========

In conclusion, insulin aspart therapy was observed to be well tolerated and efficacious in routine clinical practice in people with T2DM, whether administered as meal-time injections only, as the biphasic formulation, or in combination with a basal insulin.
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